BayPAT's Licensee Recardio already in Phase 2 Regenerative Post-Myocardial Infarction Trial of Dutogliptin in Europe and USA
BayPAT, a service provider offering services in the area of technology transfer, IP management and commercialisation, to…
BayPAT, a service provider offering services in the area of technology transfer, IP management and commercialisation, to…
NOXXON Pharma N.V. (EuroNext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by tar…
. · Keysight’s new 89600 VSA software link enables design and troubleshooting of APCO-25 and TETRA devices for…
Rainscreen facades offer a multitude of design possibilities to architects and are becoming increasingly popular. The bu…
NOXXON Pharma will disclose promising data from two independent clinical Phase IIa studies of the anti-CXCL12/SDF-1 Spie…
NOXXON Pharma announced today the publication of a new study in Cell Reports, entitled "SDF-1 Inhibition Targets the Bon…
NOXXON Pharma announced today that one of its Spiegelmer® therapeutics, olaptesed pegol (NOX-A12), received orphan drug…
NOXXON Pharma presented updated interim data sets from two independent clinical Phase IIa studies of the anti-CXCL12/SDF…
NOXXON Pharma disclosed interim data from two independent clinical phase IIa studies of the anti-CXCL12/SDF-1 Spiegelmer…
NOXXON Pharma today announced the treatment of the first cohort of three multiple myeloma (MM) patients in a Phase IIa c…